MarketCap US

US United States


Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.


Cytokinetics was founded in 1997 by James Spudich, Ronald Vale, James Sabry and Lawrence S.B. Goldstein, four scientists at Stanford, UCSD, and UCSF. Operations began in 1998.

Initially, Cytokinetics focused on the possible pharmacological targets and areas of application of drugs based on cytoskeletal proteins. Eventually, the company narrowed its focus to the mechanics of muscle biology. Cytokinetics develops muscle activators and muscle inhibitors to improve muscle function in patients with cardiovascular and neuromuscular diseases.In 2004 the company completed its initial public offering .In January 2007, Cytokinetics named Robert I. Blum as president and CEO. Prior to this, Blum has been involved in the company since its founding, with roles in business development, corporate development and R&D.In 2013, Cytokinetics finalized a licensing and discovery deal with Astellas to research treatment for muscle weakness and fatigue.In July 2020, Ji Xing Pharmaceuticals signed a financing deal with Cytokinetics, which included the rights to commercialize the drug designed to treat hypertrophic cardiomyopathies, aficamten, in China and certain neighboring regions.

Our mission is to develop therapies that are creative, narrow-focused and highly productive in order to help patients with debilitating diseases regain and preserve their muscle function and quality of life.

We strive to become a leader in the discovery, development, and commercialization of first-in-class drugs that address muscle degeneration, weakness and dysfunction as potential new treatments for debilitating diseases.

Key Team

Mr. Andrew M. Callos (Exec. VP & Chief Commercial Officer)

Dr. James A. Spudich Ph.D. (Co-Founder & Member of Scientific Advisory Board)

Mr. Jeff Lotz (VP of Sales & Operations)

Mr. Robert C. Wong (VP & Chief Accounting Officer)

Ms. Joanna Siegall (Associate Director of Corp. Communications & Investor Relations)

Ms. Kari K. Loeser J.D. (VP & Chief Compliance Officer)

Mr. Scott R. Jordan (Sr. VP of Global Marketing & Commercial Strategy)

Recognition and Awards
Some of our awards and recognition include Deloitte Technology Fast 500, 2014 Best Places to Work in San Francisco, and Best Biotechnology Company of the Year, 2014 Drug Development Summit Awards.

Leadership team

Mr. Robert I. Blum (CEO, Pres & Director)

Mr. Ching W. Jaw (Sr. VP & CFO)

Dr. Fady Ibraham Malik FACC, M.D., Ph.D. (Exec. VP of R&D)

Products/ Services
Biopharma, Biotechnology, Health Care
Number of Employees
100 - 500
South San Francisco, California, United States
Company Registration
SEC CIK number: 0001061983
20M - 100M
Traded as
Social Media
Mon Feb 26 2024

businessabc offers a global business, SMEs wiki directory blockchain, NFTs, AI powered marketplace for businesses worldwide.

Follow Us
Produced by
In collaboration with

Copyright 2023 © businessabc powered by ztudium